The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to AbelZeta ...

As community oncology evolves to deliver chimeric antigen receptor (CAR) T and bispecific therapies closer to home, support is needed to ensure patient access and precision medicine capabilities, says ...

The advent of novel cancer care therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies is ...

TURKU, FI / ACCESS Newswire / May 27, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - New preclinical data published in Scientific Reports confirms CLEVER-1 inhibition by Bexmarilimab increases ...

Faron Pharma’s bexmarilimab demonstrates immune-activating and drug-sensitizing potential in myeloid malignancies: Turku, Finland Wednesday, May 28, 2025, 16:00 Hrs [IST] Faron ...

Cell and gene therapies harbor great hopes for biomedicine. They are becoming increasingly important for diseases that are ...

Researchers are developing an in vivo approach to engineer cancer-fighting immune cells, potentially making the powerful CAR ...

The autologous immunotherapy consists of the patient’s own T cells engineered to express a chimeric antigen receptor that ...

During a live event, Samuel M. Rubinstein, MD, discussed the efficacy and safety outcomes from the KarMMa-3 trial.

Manufacturing CAR T cells in the laboratory is expensive and time-consuming. An in vivo approach could get the powerful ...

CD70 expression increased cytotoxicity of CD70 CAR NK cells against osteosarcoma; however, upregulation of CD70 had no effect on cytotoxicity.